Anglo-US pharma company picks new base at Cambridge Science Park

Conduit cites the move as a milestone in its strategic expansion plans and says it will improve the company’s development capabilities and the growth of its intellectual property portfolio.

The new lab will serve as the heart of Conduit’s workstream management system and house its management and scientific teams, the company adds, as well as streamlining is operations and maximising its out-licensing value.

CEO Dr David Tapolczay, said: “Our new laboratory serves as a dynamic base for Conduit's breakthrough endeavours, providing an optimal environment to progress and expand upon our existing asset portfolio while also facilitating a generation of new intellectual property.

“This initiative reaffirms our commitment to leading the charge in pharmaceutical innovation, collaborating closely with the celebrated scientific community in Cambridge, a prominent global life sciences hub that consistently pushes the boundaries of what is possible and develops life-changing advancements for patients.”

Conduit is a disease-agnostic life science company delivering an efficient model for compound development. It both acquires and funds the development of Phase II-ready assets and then seeks an exit through third-party license deals following successful clinical trials.

Led by a highly experienced team of pharmaceutical executives, including Dr Tapolczay and Dr Freda Lewis-Hall, Conduit believes its approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.